クリングルファーマ株式会社.

NEWS

お知らせ


Warning: Invalid argument supplied for foreach() in /home/r3716923/public_html/kringle-pharma.com/wp-content/themes/kringle_pharma/view/single/default.php on line 21
2020.12.28

IPO on the Tokyo Stock Exchange Mothers market.

Kringle Pharma, a late clinical-stage biopharmaceutical company developing recombinant human hepatocyte growth factor for incurable diseases such as acute spinal cord injury and ALS, announces the closing of its initial public offering on the Tokyo Stock Exchange Mothers market.